Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBR900 Cell Injection in Relapsed/Refractory CD20 Positive B-cell Non Hodgkin Lymphoma
NCT07073833Phase 1Recruiting
- Sponsor
- Imbioray
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of IBR900 in B-cell non-Hodgkin lymphoma (3 arms), sponsored by Imbioray. Primary endpoints: Incidence of dose limiting toxicity and Incidence and severity of adverse events. Started Jul 2025; status: recruiting.
02
Drugs
IBR900
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07073833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07073833.